Pre-Chemo |
Post-Chemo 4 cycles |
Post-Op at 1 month |
|
Liver tumours - either primary liver cancer (hepatocellular carcinoma, HCC) or cancer spreading (metastatic) to the liver as a result of colon cancer - are best treated by surgery.
Liver surgery for the removal of tumours is known as liver resection and involves removing that part of the liver affected by the tumour. The aim of liver resection is to remove all the tumour with a clear margin to obtain primary control and cure for the tumour, and is performed by surgeons specialising in liver surgery - hepatopancreaticobiliary (HPB) surgeons.
The procedure is for patients with primary hepatocellular carcinoma (HCC) and is the only form of treatment that is consistently accepted as curative treatment for this condition. Liver surgery is also possible for metastatic tumours that have spread to the liver from colorectal cancers.
In advanced cancer such as metastatic liver tumours, selected patients benefit from a combination of chemotherapy and surgery.
The HPB Surgery unit of the Department of Surgical Oncology at National Cancer Centre Singapore (NCCS)
Proven Expertise
Our HPB team is recognised as a regional leader performing between 80 and 100 HCC cases a year. Trained HPB surgeons, and a high volume of cases helps ensure quality of care and world standard results.
Advanced Methodology
NCCS's reputation for high standards and advanced methods in Liver Resection attracts a regular stream of surgeons from the Asia-Pacific region keen on learning from us.
Positive Outcomes
The prognosis of most HCC patients without treatment is a short lifespan of months. Surgery performed by our HPB team have yielded high results of up to 45% 5-year survival, comparable to worldwide standards.
For metastatic liver cancer, although considered as an advanced stage cancer, selected patients benefit from liver resection as well, and in some cases with a combination of chemotherapy and surgery.
Results at NCCS for liver resection for colorectal metastases to the liver show a survival rate of 40-45% at 5 years versus a 7-month median survival with no treatment.
Multidisciplinary Care
The surgical team works with medical and radiation oncologists to derive the optimal course of treatment for the individual patient. When surgery is not possible for HCC, our treatment options include radiofrequency ablation (RFA), and localised chemotherapy known as transarterial chemoembolisation (TACE).
For enquiries and appointments, please contact:
National Cancer Centre Singapore
Foreign Patients Services
Tel: (65) 6236 9433 Fax: (65) 6536 0611
Email: foreign_patient@nccs.com.sg
| | |
|